New Stock Issuance - Hai'an Group (Stock Code: 001233) issued at a price of 48.00 on November 14, 2025[1] - Hangzhou Qilun B (Stock Code: 200771) has a cash option declaration period from November 19 to November 25, 2025[1] - Hailianxun (Stock Code: 300277) has a buyback request declaration period from November 12 to November 18, 2025[1] Market Alerts - Pingming Technology (Stock Code: 688109) reported severe abnormal fluctuations on November 13, 2025[1] - ST Yuancheng (Stock Code: 603388) and ST Zhongzhu (Stock Code: 600568) also reported abnormal fluctuations on November 11, 2025[1] - ST Green Kang (Stock Code: 002868) and Dongbai Group (Stock Code: 600693) reported abnormal fluctuations on November 14, 2025[1] Additional Information - Multiple companies including ST Meigu (Stock Code: 000615) and ST Xiangyu (Stock Code: 600107) have ongoing announcements related to stock performance and market conditions[1][2] - The report includes links to detailed announcements for each stock, providing transparency and access to further information for investors[1]

Core Insights - The trading volume of Panlong Pharmaceutical reached 1.018 billion RMB, marking the highest level since December 27, 2022 [2] - The latest stock price increased by 2.22%, with a turnover rate of 33.91% [2] - The previous trading day's total transaction volume for the stock was 864 million RMB [2] Company Overview - Shaanxi Panlong Pharmaceutical Group Co., Ltd. was established on September 22, 1997, with a registered capital of 1.0628 billion RMB [2]

Group 1 - The core viewpoint indicates a strong performance in the Traditional Chinese Medicine (TCM) sector, with the Zhongzheng TCM Index rising by 1.22% and individual stocks like Zhongsheng Pharmaceutical increasing by 9.98% [1] - The TCM ETF has shown a consistent upward trend, achieving an 8-day consecutive rise, with the latest price reported at 1.06 yuan [1] - The National Health Commission has projected a peak in influenza cases in China during mid-December to early January, which may positively impact the TCM market [1] Group 2 - CITIC Securities anticipates that the collection of traditional Chinese medicine will continue to expand, leading to increased brand concentration in the outpatient market [1] - The TCM industry is expected to reach a healthy inventory level by Q2 2025, following a period of destocking and sales efforts [1] - Continuous growth in R&D investment by TCM companies is highlighted as a key driver for future development, with a focus on innovative TCM contributing to stable growth [1]

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days (November 11, 2025, to November 13, 2025) [2] - The company conducted an internal review and confirmed that there were no significant changes in its operational environment and that it had not discovered any undisclosed major information affecting stock prices [3][4] - The board of directors confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange listing rules, and previous disclosures do not require correction or supplementation [4]

Core Viewpoint - The stock price of Panlong Pharmaceutical has experienced an abnormal fluctuation, with a cumulative closing price deviation exceeding 20% over three consecutive trading days from November 11 to November 13, 2025 [1] Company Information - Panlong Pharmaceutical confirmed that there are no corrections or supplements needed for previously disclosed information [1] - The company's recent operational status remains normal, and there have been no significant changes in the internal and external operating environment [1]

陕西盘龙药业集团股份有限公司(以下简称"公司")股票(证券简称:盘龙药 业，证券代码:002864)交易价格连续 3 个交易日内(2025 年 11 月 11 日、2025 年 11 月 12 日、2025 年 11 月 13 日)收盘价格涨幅偏离值累计超过 20%。根据《深 圳证券交易所股票交易规则》相关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 证券代码：002864 证券简称：盘龙药业 公告编号：2025-052 陕西盘龙药业集团股份有限公司 关于公司股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 三、是否存在应披露而未披露信息的说明 针对公司股票异常波动情况，根据相关规定的要求，公司对有关事项进行了 核查，现就相关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、近期公司经营情况正常，内外部经营环境未发生重大变化； 公司董事会确认，公司目前没有任何根据《深圳证券交易所股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协 议等；董事 ...

Group 1: Product Strategy - The company focuses on key products such as the patented "Panlong Seven Tablets," which is part of a diverse portfolio covering 12 functional categories and over 100 product specifications [2] - The product range includes 19 dosage forms and 74 approved drug production numbers, along with health food and health products [2] - Future product development will emphasize functional health foods aimed at increasing bone density and other health benefits [3] Group 2: Marketing Network - The company has established a comprehensive marketing network covering over 5,000 tier-one medical institutions and more than 30,000 retail pharmacies [3] - Collaboration with over 650 commercial partners across 30 provincial administrative regions supports multi-category product sales [3] - The company is leveraging "Internet + Medicine" trends to enhance digital marketing and brand influence [3] Group 3: Traditional Chinese Medicine (TCM) Business - The company has completed the filing of 411 varieties of TCM granules, all approved by the National Medical Products Administration [3] - The company is actively advancing the listing of these products in 18 provinces, including major markets like Beijing and Shandong [3] - A combined model of self-operated teams and agents is being used to develop sales channels, focusing on key regions [3]

Core Insights - The traditional Chinese medicine sector experienced a slight increase of 0.24% on November 13, with Panlong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Stock Performance Summary - Panlong Pharmaceutical (002864) closed at 39.20, with a significant increase of 9.99% and a trading volume of 237,700 shares, amounting to a transaction value of 864 million [1] - Huasheng Technology (000790) rose by 5.09% to close at 4.54, with a trading volume of 524,900 shares [1] - Tailong Pharmaceutical (600222) saw a 4.91% increase, closing at 7.90 with a trading volume of 793,400 shares [1] - Other notable performers include Te Yi Pharmaceutical (002728) up 3.13% to 13.83, and Enwei Pharmaceutical (301331) up 2.68% to 32.62 [1] Declining Stocks Summary - ST Changyao (300391) decreased by 3.90% to 2.22, with a trading volume of 582,400 shares [2] - ST Huluwa (6655569) fell by 2.34% to 9.62, with a trading volume of 77,100 shares [2] - Weikang Pharmaceutical (300878) dropped by 2.33% to 28.05, with a trading volume of 70,500 shares [2] Capital Flow Analysis - The traditional Chinese medicine sector saw a net outflow of 681 million from main funds, while retail investors contributed a net inflow of 523 million [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its product, Panlong Qining Gel Patch, for the treatment of knee osteoarthritis [2] Group 1 - The approval includes the issuance of a "Drug Clinical Trial Approval Notice" [2] - The clinical trial will focus on the efficacy of the gel patch in treating knee osteoarthritis [2]

Market Overview - The Chinese medicine sector rose by 0.39% on November 12, with Zhongsheng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Top Performers - Zhongsheng Pharmaceutical (002317) closed at 23.38, up 10.02% with a trading volume of 1.3442 million shares [1] - Panlong Pharmaceutical (002864) closed at 35.64, up 10.00% with a trading volume of 162,700 shares [1] - Te Yi Pharmaceutical (002728) closed at 13.41, up 5.09% with a trading volume of 1.6884 million shares [1] - Other notable gainers include Jiu Zhi Tang (000989) up 4.99% and Jin Hua Co. (600080) up 4.93% [1] Underperformers - Yiling Pharmaceutical (002603) closed at 20.01, down 2.25% with a trading volume of 668,600 shares [2] - Weikang Pharmaceutical (300878) closed at 28.72, down 1.98% with a trading volume of 99,900 shares [2] - Kangmei Pharmaceutical (600518) closed at 2.09, down 1.42% with a trading volume of 2.9625 million shares [2] Capital Flow - The Chinese medicine sector saw a net inflow of 196 million yuan from institutional investors, while retail investors contributed a net inflow of 80.93 million yuan [2] - Speculative funds experienced a net outflow of 277 million yuan [2] Individual Stock Capital Flow - Zhongsheng Pharmaceutical had a net inflow of 4.03 billion yuan from institutional investors, but a net outflow of 2.13 billion yuan from speculative funds [3] - Tongrentang (600085) saw a net inflow of 1.22 billion yuan from institutional investors, with a net outflow of 508.17 million yuan from speculative funds [3] - Other stocks like Pian Zai Huang (600436) and Dong E E Jiao (000423) also experienced significant net inflows from institutional investors [3]